ARCA biopharma Files 8-K on Officer/Director Changes, Compensation
Ticker: ORKA · Form: 8-K · Filed: Feb 6, 2024 · CIK: 907654
| Field | Detail |
|---|---|
| Company | Arca Biopharma, Inc. (ORKA) |
| Form Type | 8-K |
| Filed Date | Feb 6, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: corporate-governance, executive-compensation, director-changes
TL;DR
**ARCA biopharma filed an 8-K for routine executive and director changes and compensation updates.**
AI Summary
ARCA biopharma, Inc. filed an 8-K on February 2, 2024, to report changes in its executive compensation arrangements and the departure or election of certain officers and directors. This filing is a standard disclosure for public companies and indicates routine corporate governance updates. For investors, this matters because changes in executive compensation or leadership can signal shifts in company strategy or financial health, though this specific filing appears to be a procedural update without immediate major implications.
Why It Matters
This filing signals routine corporate governance updates, which can sometimes precede strategic shifts or reflect changes in company performance, though this particular filing appears to be procedural.
Risk Assessment
Risk Level: low — This 8-K filing appears to be a standard, procedural update regarding corporate governance and compensation, not indicating any immediate high-risk events.
Analyst Insight
A smart investor would note this routine corporate governance update but would not make immediate investment decisions based solely on this filing, as it lacks specific details on the nature of the changes or their financial impact. Further investigation into the specific changes in officers, directors, and compensation arrangements would be prudent if more detailed information becomes available.
Key Players & Entities
- ARCA biopharma, Inc. (company) — the registrant filing the 8-K
- February 02, 2024 (date) — date of earliest event reported
- Delaware (company) — state of incorporation for ARCA biopharma, Inc.
- 000-22873 (dollar_amount) — Commission File Number
- 36-3855489 (dollar_amount) — IRS Employer Identification No.
- 10170 Church Ranch Way Suite 100, Westminster, Colorado, 80021 (company) — address of Principal Executive Offices
- (720) 940-2200 (dollar_amount) — Registrant’s Telephone Number
- ABIO (company) — Trading Symbol for Common Stock
- The Nasdaq Global Market (company) — exchange where Common Stock is registered
FAQ
What is the primary purpose of ARCA biopharma, Inc.'s 8-K filing dated February 2, 2024?
The primary purpose of ARCA biopharma, Inc.'s 8-K filing dated February 2, 2024, is to report on the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' and 'Financial Statements and Exhibits' as per the Item Information.
What is ARCA biopharma, Inc.'s trading symbol and on which exchange is its common stock registered?
ARCA biopharma, Inc.'s trading symbol is ABIO, and its common stock is registered on The Nasdaq Global Market.
What is the business address and phone number of ARCA biopharma, Inc. as stated in the filing?
The business address of ARCA biopharma, Inc. is 10170 Church Ranch Way, Suite 100, Westminster, Colorado, 80021, and its telephone number is (720) 940-2200.
What is the state of incorporation for ARCA biopharma, Inc.?
ARCA biopharma, Inc. is incorporated in Delaware, as stated in the filing.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 02, 2024.
Filing Stats: 551 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-02-06 16:15:10
Filing Documents
- abio-20240202.htm (8-K) — 39KB
- 0000950170-24-011737.txt ( ) — 149KB
- abio-20240202.xsd (EX-101.SCH) — 24KB
- abio-20240202_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 104 Cover Page Interactive Data File. The cover page XBRL tags are embedded within the inline XBRL document (contained in Exhibit 101).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARCA biopharma, Inc. (Registrant) Date: February 6, 2024 By: /s/ C. Jeffrey Dekker Name: C. Jeffrey Dekker Title: Chief Financial Officer